COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Income Growth Analysis including revenue, gross profit, operating profit, net profit, EPS, and other financial metrics. Compare income growth against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Income Growth Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.

Revenue Growth

3.75%

Decreased from previous period

Growth of 3.75% versus flat Healthcare revenue. Walter Schloss would verify growth quality.

Cost of Revenue Growth

2.25%

Decreased from previous period

Cost growth of 2.25% versus flat Healthcare costs. Walter Schloss would verify cost control.

Gross Profit Growth

10.29%

Increased from previous period

Growth of 10.29% versus flat Healthcare gross profit. Walter Schloss would verify quality.

Gross Margin Ratio Growth

6.31%

Increased from previous period

Margin change of 6.31% versus flat Healthcare margins. Walter Schloss would verify quality.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Selling & Marketing Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Other Expenses Growth

-80.56%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Operating Expenses Growth

3.07%

Decreased from previous period

Operating expenses growth 50-90% of Healthcare median of 3.97%. Mohnish Pabrai would examine discipline.

Total Costs & Expenses Growth

2.38%

Decreased from previous period

Total costs growth 50-90% of Healthcare median of 4.65%. Mohnish Pabrai would examine discipline.

Interest Expense Growth

23.08%

Increased from previous period

Interest expense change of 23.08% versus flat Healthcare costs. Walter Schloss would verify control.

Depreciation & Amortization Growth

-37.70%

Decreased from previous period

D&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency.

EBITDA Growth

11.03%

Increased from previous period

EBITDA change of 11.03% versus flat Healthcare. Walter Schloss would verify quality.

EBITDA Margin Growth

7.02%

Increased from previous period

Margin change of 7.02% versus flat Healthcare. Walter Schloss would verify quality.

Operating Income Growth

42.26%

Increased from previous period

Income change of 42.26% versus flat Healthcare. Walter Schloss would verify quality.

Operating Margin Growth

37.12%

Increased from previous period

Margin change of 37.12% versus flat Healthcare. Walter Schloss would verify quality.

Other Income/Expenses Growth

-74.51%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Pre-Tax Income Growth

11.00%

Increased from previous period

Income change of 11.00% versus flat Healthcare. Walter Schloss would verify quality.

Pre-Tax Margin Growth

6.99%

Increased from previous period

Margin change of 6.99% versus flat Healthcare. Walter Schloss would verify quality.

Income Tax Expense Growth

-10.75%

Decreased from previous period

Tax expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Net Income Growth

26.24%

Increased from previous period

Income change of 26.24% versus flat Healthcare. Walter Schloss would verify quality.

Net Margin Growth

21.68%

Increased from previous period

Margin change of 21.68% versus flat Healthcare. Walter Schloss would verify quality.

EPS Growth

26.24%

Increased from previous period

EPS change of 26.24% versus flat Healthcare. Walter Schloss would verify quality.

Diluted EPS Growth

26.24%

Increased from previous period

Diluted EPS change of 26.24% versus flat Healthcare. Walter Schloss would verify quality.

Share Count Growth (Basic)

0.00%

Increased from previous period

Share count change of 0.00% versus stable Healthcare. Walter Schloss would verify approach.

Share Count Growth (Diluted)

No Data

No Data available this quarter, please select a different quarter.

Select Chart Metric:

3349.T Income Growth Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Revenue Growth

3.75%

Decreased from previous period

Growth of 3.75% versus flat Healthcare revenue. Walter Schloss would verify growth quality.

Cost of Revenue Growth

2.25%

Decreased from previous period

Cost growth of 2.25% versus flat Healthcare costs. Walter Schloss would verify cost control.

Gross Profit Growth

10.29%

Increased from previous period

Growth of 10.29% versus flat Healthcare gross profit. Walter Schloss would verify quality.

Gross Margin Ratio Growth

6.31%

Increased from previous period

Margin change of 6.31% versus flat Healthcare margins. Walter Schloss would verify quality.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Selling & Marketing Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Other Expenses Growth

-80.56%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Operating Expenses Growth

3.07%

Decreased from previous period

Operating expenses growth 50-90% of Healthcare median of 3.97%. Mohnish Pabrai would examine discipline.

Total Costs & Expenses Growth

2.38%

Decreased from previous period

Total costs growth 50-90% of Healthcare median of 4.65%. Mohnish Pabrai would examine discipline.

Interest Expense Growth

23.08%

Increased from previous period

Interest expense change of 23.08% versus flat Healthcare costs. Walter Schloss would verify control.

Depreciation & Amortization Growth

-37.70%

Decreased from previous period

D&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency.

EBITDA Growth

11.03%

Increased from previous period

EBITDA change of 11.03% versus flat Healthcare. Walter Schloss would verify quality.

EBITDA Margin Growth

7.02%

Increased from previous period

Margin change of 7.02% versus flat Healthcare. Walter Schloss would verify quality.

Operating Income Growth

42.26%

Increased from previous period

Income change of 42.26% versus flat Healthcare. Walter Schloss would verify quality.

Operating Margin Growth

37.12%

Increased from previous period

Margin change of 37.12% versus flat Healthcare. Walter Schloss would verify quality.

Other Income/Expenses Growth

-74.51%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Pre-Tax Income Growth

11.00%

Increased from previous period

Income change of 11.00% versus flat Healthcare. Walter Schloss would verify quality.

Pre-Tax Margin Growth

6.99%

Increased from previous period

Margin change of 6.99% versus flat Healthcare. Walter Schloss would verify quality.

Income Tax Expense Growth

-10.75%

Decreased from previous period

Tax expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Net Income Growth

26.24%

Increased from previous period

Income change of 26.24% versus flat Healthcare. Walter Schloss would verify quality.

Net Margin Growth

21.68%

Increased from previous period

Margin change of 21.68% versus flat Healthcare. Walter Schloss would verify quality.

EPS Growth

26.24%

Increased from previous period

EPS change of 26.24% versus flat Healthcare. Walter Schloss would verify quality.

Diluted EPS Growth

26.24%

Increased from previous period

Diluted EPS change of 26.24% versus flat Healthcare. Walter Schloss would verify quality.

Share Count Growth (Basic)

0.00%

Increased from previous period

Share count change of 0.00% versus stable Healthcare. Walter Schloss would verify approach.

Share Count Growth (Diluted)

No Data

No Data available this quarter, please select a different quarter.

Select Chart Metric: